Effects of pituitary adenylate cyclase activating polypeptide and its fragments on retinal degeneration induced by neonatal monosodium glutamate treatment.
Pituitary adenylate cyclase activating polypeptide (PACAP) is a member of the growing family of neurotrophic and neuroprotective factors playing important roles during neuronal development and protection against different types of injuries, such as Parkinson's disease, excitotoxicity, and ischemia. As shown with other neuronal tissues, we provide evidence that PACAP is protective in the retina against toxic injury induced by monosodium glutamate (MSG) in vivo. The need for characterization of its fragments and analogues has recently been emphasized. The aim of the present study was to compare the effects of the physiologically occurring fragments PACAP1-38 and 1-27 and the widely used antagonists (PACAP6-38 and 6-27) in retinal degeneration induced by MSG in neonatal pups. Histological analysis showed that MSG treatment caused the degeneration of the entire inner plexiform layer and the inner nuclear and ganglion cell layers seemed fused. The total thickness of the retina was significantly reduced. Similar and substantial protective effects could be observed after three treatments with PACAP1-38 and 1-27, while MSG toxicity was further aggravated by the PACAP antagonists PACAP6-38 and 6-27. Glutamate-induced toxicity is known to play a role in several retinal pathologies. Our results provide further evidence for the effectiveness of the endogenously present PACAP forms in counteracting retinotoxicity and call for further studies leading to the discovery of potent analogues that could be used in human ophthalmic diseases.
Atlasz
Tamás
T
Department of Experimental Zoology and Neurobiology, University of Pécs, Pécs, Hungary.
Szabadfi
Krisztina
K
Reglodi
Dóra
D
Kiss
Péter
P
Tamás
Andrea
A
Tóth
Gábor
G
Molnár
Alexandra
A
Szabó
Klaudia
K
Gábriel
Róbert
R
D000818:Animals; D000831:Animals, Newborn; D010446:Peptide Fragments / Q000627:therapeutic use*; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D012162:Retinal Degeneration / Q000139:chemically induced* / Q000188:drug therapy*; D012970:Sodium Glutamate / Q000494:pharmacology*
D010446:Peptide Fragments; D051219:Pituitary Adenylate Cyclase-Activating Polypeptide; D012970:Sodium Glutamate